Invited Speakers:
|
|
KEYNOTE: Joseph D. Purvis, M.D.,
Executive Director Clinical Research,
Section Head Medicines and Sciences
AztraZeneca Pharmaceuticals
Stuart Emanuel, Cancer Therapeutics Research
Johnson & Johnson Pharmaceutical Research & Development
Joel S. Hayflick, Ph.D., Principal Scientist
ICOS Corporation
Zhenping Zhu, M.D., Ph.D., Vice President Antibody Technology
ImClone Systems, Inc.
Ricky Johnstone, Laboratory Head
Peter MacCallum Cancer Centre
Lyubomir Vassilev, Ph.D, Senior Research Leader, Discovery Oncology
Hoffmann-La Roche, Inc.
William Moore, Ph.D., Chief Scientific Officer and Vice President, Research & Development
Locus Pharmaceuticals
NATIONAL CANCER INSTITUTE – MOUSE MODELS OF HUMAN
CANCER CONSORTIUM
Michael Lahn, M.D., Medical Advisor
Eli Lilly Research Laboratories
Suxing Liu, Ph.D, Biological Research-Oncology
Schering-Plough Research Institute
William Siders, Ph.D., Senior Scientist, Immunotherapy Research Group
Genzyme Corporation
Andrei Thomas-Tikhonenko, Ph.D., Assistant Professor of Pathology
University of Pennsylvania
Damir Janigro, Ph.D., Professor of Molecular Medicine
Cleveland Clinic Foundation
Axel Hoos, M.D., Ph.D., Senior Director, Clinical Development,
Antigenics Inc.
Pearl S. Huang, Ph.D., Oncology and Proliferative Disease, MMPD, CEDD
GlaxoSmithKline
Dale Ludwig, Ph.D., Senior Director, Department of Cell Engineering & Expression
ImClone Systems, Inc.
Jocelyn Holash, Associate Director of Tumor Angiogenesis,
Regeneron Pharmaceuticals, Inc.
Yigong Shi Ph.D, Professor, Department of Molecular Biology
Princeton University, Thomas Lewis Laboratory
Peter Atadje
Novartis Research Institute
|
|